Title:
HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2021/018194
Kind Code:
A1
Abstract:
Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are BCR-ABL I nhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.
More Like This:
Inventors:
ZHOU YUNLONG (CN)
TANG GUOZHI (CN)
LI CHAO (CN)
LIU FANG (CN)
JING YU (CN)
WANG RENLIN (CN)
JIAO LINGLING (CN)
TANG GUOZHI (CN)
LI CHAO (CN)
LIU FANG (CN)
JING YU (CN)
WANG RENLIN (CN)
JIAO LINGLING (CN)
Application Number:
PCT/CN2020/105519
Publication Date:
February 04, 2021
Filing Date:
July 29, 2020
Export Citation:
Assignee:
ASCENTAGE PHARMA SUZHOU CO LTD (CN)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
ASCENTAGE PHARMA GROUP CORP LTD (CN)
International Classes:
C07D403/14; A61K31/475; A61P35/00; C07D235/16; C07D403/04; C07D405/14; C07D409/14; C07D417/04; C07D471/04; C07D498/04; C07D513/04
Domestic Patent References:
| WO2020061086A2 | 2020-03-26 | |||
| WO2013171641A1 | 2013-11-21 | |||
| WO2013171640A1 | 2013-11-21 | |||
| WO2018121610A1 | 2018-07-05 | |||
| WO2018167695A1 | 2018-09-20 | |||
| WO2017186148A1 | 2017-11-02 |
Foreign References:
| CN104302634A | 2015-01-21 |
Other References:
SCHOEPFER JOSEPH, JAHNKE WOLFGANG, BERELLINI GIULIANO, BUONAMICI SILVIA, COTESTA SIMONA, COWAN-JACOB SANDRA W., DODD STEPHANIE, DR: "Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1", J. MED. CHEM., vol. 61, no. 18, 23 August 2018 (2018-08-23), pages 8120 - 8135, XP055777027, ISSN: 0022-2623, DOI: :10.1021/acs.jmedchem.8b01040
See also references of EP 3947369A4
See also references of EP 3947369A4
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: